Introduction
Active Crohn's disease (CD) and ulcerative colitis (UC) are associated with vitamin D deficiency in many [1] [2] [3] but not all studies. 4, 5 Vitamin D deficiency is defined by a 25-hydroxyvitamin D [25(OH)D] concentration in serum, or plasma, cut-off of <50 nmol/l. 6, 7 There are a number of factors that could account for the association between vitamin D deficiency and active inflammatory bowel disease (IBD) such as corticosteroid use, reduced sunlight exposure and reduced vitamin D oral intake or absorption. 8 Vitamin D is acquired from diet, or through dermal synthesis, predominantly in the form of vitamin D 3 . Vitamin D 2 is produced by ultraviolet (UV) irradiation of ergosterols in plants but contributes modestly to the total circulating vitamin D, except in populations with vitamin-D 2 -supplemented food. Vitamins D 2 and D 3 undergo comparable metabolism, so when vitamin D 3 metabolism is referred to, it also applies to vitamin D 2 metabolites. Vitamin D 3 undergoes 25-hydroxylation in the liver by the cytochrome p450 enzyme, CYP2R1, to produce 25(OH)D 3 , which has little biological activity. The majority (85-90%) of 25(OH)D 3 circulates tightly bound to the vitamin-D-binding protein (VDBP). 9 The remaining non-VDBP-bound fraction (bioavailable 25(OH)D 3 ) is bound to albumin with less than 1% of 25(OH)D 3 unbound or free. It has been proposed that the free, or bioavailable, 25(OH)D 3 may be more physiologically relevant than total 25(OH)D 3 , although this has not been formally evaluated. 9, 10 Circulating 25(OH)D 3 is further hydroxylated in the kidney and extra-renal tissues by the 1α-hydroxylase CYP27B1 to produce the metabolically active 1,25(OH) 2 3 ). While 24-hydroxylase CYP24A1 is most abundant in the proximal and distal tubules of the kidney, it has also been detected in essentially all vitamin D target tissues including the colon.
The association between active IBD and vitamin D deficiency has led investigators to study vitamin D supplementation as a treatment for IBD in a series of small studies that have yielded mixed results. [11] [12] [13] In the largest study, a randomized, double-blind placebo-controlled trial, 94 CD patients in remission were randomized to receive either 1200 IU vitamin D 3 , or placebo, once daily for 1 year. Vitamin D supplementation reduced the rate of clinical relapses from 29% to 13% (p = 0.06). 11 A further study in UC supplementing participants with 40,000 IU vitamin D 3 for 8 weeks, using an inactive UC and non-IBD control groups, found a reduction in faecal calprotectin and simple clinical colitis score, but not the partial Mayo score. 12 However, a pilot randomized open-label study treated 124 UC and CD patients with either 150,000 IU vitamin D 3 daily, elemental calcium or no treatment and showed no improvement in disease activity scores with vitamin D supplementation. 13 Our group has recently shown in a mouse model, that circulating 25(OH)D 3 and the active metabolite 1,25(OH) 2 D 3 acutely drop after inducing colitis with dextran sodium sulphate, associated with an increase in gene expression of the CYP24A1. 14 Further, in a large Australian cohort of patients with CD in steroid-free remission, a low 25(OH)D level did not predict subsequent relapse which would otherwise be expected if vitamin D deficiency predisposed to intestinal inflammation. 15 We hypothesized that the circulating serum 25(OH)D 3 concentrations will be lower in patients with active CD as a result of active catabolism of 25(OH)D 3 to downstream metabolites, such as 24,25(OH) 2 D 3 . Further, we hypothesized that these changes will reverse with resolution of inflammation.
The aim of this study was to characterise the effect of intestinal inflammation on the metabolism of vitamin D, by examining a range of vitamin D metabolites in the setting of active and inactive CD.
Material and methods

Patients and design
Patients with CD were prospectively recruited from the IBD clinic at St. Vincent's Hospital, Sydney, Australia, between March and June 2017. All patients were diagnosed with CD according to standard clinical, endoscopic, and radiological criteria 16 and were phenotyped according to the 'Montreal Classification'. Patients were aged between 16 and 60 years and had either colonic (Montreal L2) or ileocolonic (Montreal L3) disease. We included two groups of patients; those with moderate-severe disease activity and those in remission. Moderate-severe disease activity was defined by a CD activity index (CDAI) ⩾ 220 in addition to an objective marker of active inflammation [C-reactive protein (CRP) ⩾ 10 mg/l, faecal calprotectin > 250 µg/g or active ulceration seen at ileocolonoscopy within 3 months]. Inactive disease was defined by CDAI < 150 and either CRP < 10 mg/l, faecal calprotectin < 150 µg/g; or no ulceration at ileocolonoscopy within 3 months. Patients were excluded if they were on vitamin D supplements or corticosteroids within 4 weeks of recruitment, if they were pregnant, had short bowel syndrome, isolated small bowel CD or remission that was induced by colonic resection.
At enrolment, baseline data, including demographics, disease and medication history were collected. Participants completed diet and C Haifer, IC Lawrance et al.
journals.sagepub.com/home/tag 3 sunlight questionnaires at baseline and at 6 months. Blood was collected, and serum stored from all participants at enrolment and after 6 months ( Figure 1 ). Vitamin D metabolite testing was performed after the study period, effectively blinding treating physicians to the vitamin D results.
Participants were followed for a period of 6 months. Treatment of CD during the study period, including the use of corticosteroids, was left to the discretion of the treating physician and recorded in the study records. If patients commenced on vitamin D supplementation during the study period, then they were not included in the follow-up analysis. Disease relapse was defined as greater than a 100-point rise in CDAI to at least 150 with associated objective markers of relapse (CRP ⩾ 10 mg/l, faecal calprotectin > 250 µg/g or active ulceration seen at ileocolonoscopy). Development of remission from active disease was defined as a CDAI < 150 and either CRP < 10 mg/l, faecal calprotectin < 150 µg/g or no ulceration at ileocolonoscopy.
Peripheral blood was collected by venepuncture. Routine laboratory haematology and biochemistry tests were performed immediately, and a serum sample of 1-1.5 ml was stored at −20°C for later analysis of vitamin D metabolites. assessment included questions related to skin colour and tanning characteristics, time spent outdoors between the hours of 10 am and 3 pm in the preceding month on weekdays and weekends, area of skin exposed and use of sunscreen. Vitamin D intake was measured using a food frequency questionnaire of foods with highest vitamin D content. At study exit, a follow-up questionnaire (Supplementary Data Content 1) was administered including details of symptoms, medications, smoking, sun exposure and dietary intake.
Biochemical measurements
Data on ambient levels of ultraviolet (UV) radiation
Data on levels of ambient UV radiation were provided by the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) and measured as measured in Standard Erythemal Doses (available at www.arpansa.gov.au/our-services/ monitoring/ultraviolet-radiation-monitoring/ ultraviolet-radiation-dose)
Statistical consideration and analysis
The study was powered to detect a difference in serum 25(OH)D 3 levels between the two groups at baseline. Using the results of the study by Harries and colleagues 21 that showed lower levels of 25(OH)D 3 in CD patients, the study was powered to detect an 8% difference in the 25(OH)D 3 level between the two groups with an α of 0.05 and β of 0.80. On this basis, we determined a sample size of 27 per group was required. Longitudinal analysis of the 6-month data was exploratory and the study was not powered for this analysis. A score for vitamin D obtained from sunlight exposure was calculated using a modified method described by Cargill and colleagues. 20 The reported time spent outdoors between 10 am and 3 pm during an average week was combined with a weighted UV multiplier based on the month the data were collected. Finally, a multiplier was applied based on the reported clothing coverage to estimate body surface area exposed (see Supplementary Data Content 2 for further details).
A score for vitamin D intake was generated from dietary sources using the dietary questionnaires combined with the reported vitamin D content of foods as described by the Nutritional Tables  (NUTTAB) 
Results
Patient characteristics
Fifty-nine consecutive patients with CD meeting the inclusion criteria were identified (Figure 2 ). Five patients were excluded either due to the inability to comply with required follow up or current vitamin D supplementation that was not identified on screening. A total of 54 participants were included in the final analysis; 27 with active disease and 27 with inactive disease. Thirty-one patients (54%) were male and the mean age was 37 years (Table 1 ). All patients had colonic involvement, with 24 (42%) having isolated colonic disease (Montreal Classification L2) and the remaining 30 (58%) having ileocolonic disease (Montreal Classification L3). Ten patients (17%) had a history of perianal CD, though no patients had active perianal disease. As per the inclusion criteria, none of the patients were receiving vitamin D supplementation or corticosteroids for 4 weeks prior to enrolment.
Of the 27 patients with active disease, 24 (89%) were included based on a recent ileocolonoscopy showing active disease, with the remainder having an elevated faecal calprotectin.
There were no significant differences in age, disease phenotype, previous intestinal resections, 
Analysis at 6-month follow up
Follow-up analysis, including repeated sunlight and dietary questionnaires and measurements of vitamin D metabolites, was completed for 41 patients. At the time of follow up, no patients were taking corticosteroids. Of the 17 patients with active disease at enrolment that completed follow up, 13 (76%) developed remission during the follow-up period. Four patients had persistently active disease and no patients with inactive disease at the start of the study period developed a flare of disease (Figure 2 ).
In patients with active disease who developed clinical remission during the follow-up period, there was a significant increase in the mean 25(OH)D 3 from baseline to 6 months, such that the mean 25(OH)D 3 returned to sufficient levels as defined by the US Endocrine Society [25(OH) D 3 ⩾ 75 nmol/l]. After controlling for the change in external determinants of vitamin D, levels of 25(OH)D 3 increased significantly more in patients whose disease activity improved as compared with patients who had persistently active, or inactive, disease throughout the study period ( Table 4 ). The increase in 25(OH)D 3 was accompanied by a significant increase in the mean 24,25(OH) 2 D 3 concentration to a level that was similar to levels found in patients who remained in remission throughout the study (p = 0.96; data not shown).
Discussion
To date, there has been debate on whether vitamin D deficiency is causally linked to the development, activity and complications of IBD. Many of the association studies reporting this link do not adequately control for potential confounders such as corticosteroid use, vitamin D intake and sunlight exposure. This is the first study, to our knowledge, to prospectively examine the metabolism of vitamin D using the gold standard LC/ MS/MS in a cohort of patients with CD not on corticosteroids with similar disease distribution and also carefully controlling for sunlight exposure and vitamin D intake to determine the independent effect of intestinal inflammation on circulating vitamin D metabolite levels.
Contrary to existing literature, we did not find reduced 25(OH)D 3 levels in patients with active CD despite an appropriate sample size to detect this difference. There are several possible explanations for this. First, the location of the study, Sydney, Australia (latitude 33° 87' S), has a much higher UV Index compared with that of many North American and European cities from where the existing literature originates. For example, the average summer UV Index in Sydney is 9-11, whereas in Denmark, where one of the earlier association studies was performed, the average summer UV Index is 5-6. 1, 22, 23 Thus, the Sydney population is likely to be more resistant to developing vitamin D deficiency, even in the face of active inflammation. Second, this study excluded patients on corticosteroids at baseline which is known to reduce 25(OH)D 3 levels and has been a confounding factor in the published literature. 8 For example, in the previously mentioned cross-sectional Danish study, 25(OH) D levels were inversely correlated with disease activity as measured by CDAI and CRP. While the authors examined the effect of smoking and BMI as potential confounders, the use of corticosteroids was not discussed. 1 returned to levels that were similar to those seen in patients who remained with inactive disease throughout the study period. In one other study, 24,25(OH) 2 D 3 metabolites were measured using a radioimmunoassay in well-nourished and undernourished adult CD patients (n = 40) compared The change in vitamin D metabolite levels over the 6 months from baseline to follow up is shown for participants that remained in active disease, inactive disease or were originally in active disease but achieved remission. Data were analysed using a multiple linear regression model with the following adjustments: There was a trend for increased VDBP levels and lower calculated bioavailable vitamin D in the setting of active disease compared with inactive disease. This is consistent with our previous reports of elevated VDBP levels predicting subsequent disease relapse in patients with CD, as well as seen in murine models of colitis. 14 One potential mechanism for this association is that the presence of lower bioavailable vitamin D may impair innate and adaptive immune responses as well as barrier function, impeding the resolution of inflammation. In contrast to our findings, VDBP levels fall in the setting of critical illness, not specifically related to gastrointestinal disease. 25 This difference in observations is that the rise in VDBP concentration in the setting of CD may be uniquely related to a process that occurs in intestinal inflammation. Furthermore, in this study, we estimated bioavailable vitamin D through validated calculations; however, future studies should utilize techniques to directly measure circulating levels.
Several limitations warrant mention. First, the sample size was small, but we reached the predetermined sample size for the baseline cross-sectional analysis. It is possible that with a larger cohort, differences in 25(OH)D 3 levels may have been observed; however, this is unlikely given the small, clinically insignificant difference seen between groups seen (0.08 mmol/l) and p value obtained (p = 0.91).
None of the participants with inactive disease relapsed during the follow-up period. This is not unexpected and consistent with recent literature showing that <10% of patients develop disease flare over a 1-year period when in stable remission on immunosuppression, especially with anti-TNF treatment. 26 Therefore, we were unable to demonstrate changing concentrations of 25(OH) D and its metabolites with disease flare. With such infrequent relapses, a very large study population would have been required to adequately power a longitudinal study. Despite this, our exploratory analysis did reveal significant changes in several parameters. A longer follow up or a larger cohort may further delineate the impact of disease relapse on vitamin D metabolites.
Measuring external vitamin D sources using retrospective questionnaire data has limitations with UV dosimeters remaining the gold standard for measuring exposure to UV-B radiation. However, previous studies have shown that measurements from UV dosimeters explained only 8.3% of the journals.sagepub.com/home/tag 11 variance in 25(OH)D levels. 27 The questionnaires used in this study have been validated against UV-dosimeter data and thus, are felt to be a reasonable estimate of sunlight exposure for the purpose of this study. 
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